Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cell study sheds light on childhood disease

NCT ID NCT02317133

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined blood samples from 100 children with Henoch Schönlein Purpura (HSP) and a control group to see if regulatory T cells (Tregs) are missing or not working properly. The goal was to learn more about the disease, not to test a new treatment. Researchers measured Treg levels, immune markers, and gut bacteria to find possible clues about HSP.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Feb 2015

Finished

Jul 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Three different populations will be included in this study: (A) patients presenting with an acute episode of Henoch Schönlein purpura; (B) patients who have had an episode of Henoch Schönlein purpura in the past, but currently present with no symptoms; (C) a group of control patients recruted from elective surgery candidates at the participating hospitals.

Ages

3 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General inclusion criteria for all sub-populations included in the study * The child (with age- and comprehension-skill-appropriate information) and parents (or persons exercising parental authority) have been informed about the implementation of the study, its objectives, constraints and patient rights * The child (depending on age) and parents (or persons exercising parental authority) have given their free and informed consent and signed the consent * The patient must be insured or beneficiary of a health insurance plan Inclusion criteria for population A: Henoch Schönlein purpura, acute episodes * The diagnosis of Henoch Schönlein purpura was made by a physician according to the EULAR / PRES / PRINTO 2010 criteria (purpura predominantly on the lower limbs associated with one of the following criteria: abdominal pain, arthralgia or arthritis, kidney damage or suggestive histology (immune deposits dominated by Immunoglobulin A (IgA)) * The patient is not treated via immunosuppression (steroids or other immunosuppressive / biotherapy) and has not been treated like this for at least 15 days Inclusion criteria for population B: Henoch Schönlein purpura in remission * The diagnosis of Henoch Schönlein purpura was made by a physician according to the EULAR / PRES / PRINTO 2010 criteria * The patient has has a Henoch Schönlein purpura episode in the past, and no longer has any symptoms of the disease * The patient is not treated via immunosuppression (steroids or other immunosuppressive / biotherapy) and has not been treated like this for at least 15 days Inclusion criteria for population C: controls * Subjects free from infectious, inflammatory or autoimmune diseases * Candidates for elective surgery (circumcision, urological surgery, removal of tonsils and adenoids) Exclusion Criteria: * The patient is participating in another interventional study or is in an exclusion period determined by a previous study * The child refuses to participate in the study * Parents (or persons with parental responsibility if any) refuse to sign the consent * It is impossible to correctly inform the patient or his/her parents (or persons with parental authority if any) * The patient has another inflammatory or autoimmune disease * Patient on immunosuppressive / biotherapy treatments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Henoch-Schönlein purpura are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU de Montpellier - Hôpital Lapeyronie

    Montpellier, 34295, France

  • CHRU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.